Patent ID: 6011003
Filing Date: 2000-01-04
Classification: A61K,A61P,C07K

Abstract:
An isolated, soluble polypeptide selected from the group consisting of:(a) a polypeptide having an amino acid sequence consisting of amino acid residues 1 to 553 of SEQ ID NO:3;(b) a polypeptide having an amino acid sequence consisting of amino acid residues 1 to 517 of SEQ ID NO:3;(c) a polypeptide having an amino acid sequence consisting of amino acid residues 1 to 553 of SEQ ID NO:3 with the addition of the sequence ELSNFECLHPCSQE (SEQ ID NO:16) at its C-terminal end;(d) a polypeptide having an amino acid sequence consisting of amino acid residues 1 to 517 of SEQ ID NO:3 with the addition of the sequence LPPADSSFMLPPTSFSSNYFHFLP (SEQ ID NO:17) at its C-terminal end; and(e) a truncated variant polypeptide of (a), (b), (c) or (d); wherein said truncated variant polypeptide consists of no more than five complete immunoglobulin-like domains; and wherin said trucated variant polypeptide both binds to and exerts an inhibitory effect on VEGF.